Why GlaxoSmithKline Pharmaceuticals's stock is down despite strong FY25 results
GlaxoSmithKline Pharmaceuticals's stock slipped 2% to ₹2,680.10 on Thursday, right after the company posted impressive results for FY25.
The stock is part of the NIFTY MIDCAP 150 index.
Investors react to mixed Q1FY26 numbers
Despite solid growth—revenue jumped 8.5% to ₹3,749 crore and net profit soared 57% to ₹927 crore—investors still pushed the share price down.
Even in Q1FY26, profit kept rising while revenue dipped a bit.
For anyone curious about how markets work, it's a reminder that good results don't always mean instant rewards.
GSK's balance sheet looks solid
GSK is keeping things steady: assets and liabilities are balanced at ₹4,108 crore, reserves have grown to ₹1,781 crore, and dividends keep coming (₹12 per share in October 2024 plus a final ₹42 per share in May 2025).
So while the market can be unpredictable short-term, GSK seems focused on rewarding its shareholders for sticking around.